Telix's TLX250-CDx (Zircaix) BLA for Kidney Cancer Imaging Gains FDA Priority Review
Key Insights
Telix Pharmaceuticals has submitted a Biologics License Application (BLA) to the FDA for TLX250-CDx (Zircaix) for kidney cancer (search) imaging.
TLX250-CDx is an investigational PET drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (search) (ccRCC (search)).
The FDA granted Priority Review and provided a PDUFA date of August 27, 2025, paving the way for a potential U.S. commercial launch in 2025.
Telix Pharmaceuticals is one step closer to potentially revolutionizing kidney cancer (search) management as the FDA accepts the Biologics License Application (BLA) for TLX250-CDx (Zircaix), an innovative PET imaging agent. The FDA has granted Priority Review and set a PDUFA date of August 27, 2025, signaling the potential for a U.S. commercial launch in 2025. This development marks a significant advancement in the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (search) (ccRCC (search)), the most common and aggressive form of kidney cancer.
Addressing Unmet Needs in Kidney Cancer Diagnosis
Currently, diagnosing and characterizing ccRCC (search) often requires invasive procedures. TLX250-CDx, if approved, would be the first commercially available targeted PET agent specifically for kidney cancer (search) in the U.S., offering a non-invasive alternative. The agent works by selectively binding to carbonic anhydrase IX (search) (CAIX (search)), a protein highly expressed in ccRCC cells, enabling high tumor-to-background ratio imaging and consistent interpretation.
Robust Phase III Trial Results
The BLA submission is supported by data from the global Phase III ZIRCON trial, which enrolled 300 patients, with 284 being evaluable. The trial met all primary and secondary endpoints, demonstrating:
- Sensitivity: 86%
- Specificity: 87%
- Positive Predictive Value: 93%
These results, observed across three independent radiology readers, highlight TLX250-CDx's ability to accurately detect the clear cell phenotype, even in small and difficult-to-detect lesions. The findings were published in The Lancet Oncology, underscoring the agent's potential to be practice-changing.
Expert Commentary
Kevin Richardson, Chief Executive Officer, Precision Medicine at Telix, expressed enthusiasm about the FDA's decision, stating, "We are delighted that the FDA has accepted this BLA as it moves us one step closer to bringing our breakthrough product to patients... By providing a more definitive clinical diagnosis for renal masses, we believe that Zircaix will help physicians make more timely and confident patient management decisions and more quickly provide patients with a clear understanding of their disease and treatment options."
Ongoing Access and Future Implications
Telix is committed to providing access to TLX250-CDx through expanded access programs in the U.S., named patient programs in Europe, and special access schemes in Australia. While TLX250-CDx is currently for investigational use only, its potential approval could significantly improve the diagnostic landscape for kidney cancer (search), reducing the need for invasive procedures and enabling more informed treatment decisions.